China NMPA Inspection - Chengdu Mingpeizhuang Biotechnology Co., Ltd. - November 07, 2024

The National Medical Products Administration (NMPA) recently conducted an unannounced inspection of Chengdu Mingpeizhuang Biotechnology Co., Ltd., with the findings announced on November 7, 2024. The inspection revealed significant non-compliance with China's cosmetics regulatory framework. Specifically, the company was found to be in violation of the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Quality Management Standards." The most critical issue identified was serious deficiencies within its production quality management system, indicating a failure to adhere to established manufacturing and quality control protocols for cosmetic products. In response to these findings, the NMPA has taken prompt regulatory action to safeguard public health and ensure product safety. The Sichuan Provincial Drug Administration has been directed to initiate a thorough investigation into the company's suspected illegal activities and to impose appropriate penalties as mandated by law. Furthermore, Chengdu Mingpeizhuang Biotechnology Co., Ltd. has received an official order to immediately suspend its production and operational activities. This suspension is a mandatory prerequisite for the company to address and rectify all identified problems and deficiencies within its quality management system before resuming operations. This enforcement action underscores the NMPA's commitment to stringent oversight of the cosmetics industry in China.